Racivir
| Code | Size | Price |
|---|
| TAR-T28499-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28499-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28499-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Racivir is a reverse transcriptase inhibitor. Racivir is anabolized to the active 5'-triphosphate in cells. HBV replication is equally inhibited in cultures incubated with Racivir when the compound is added 24 h preinfection, at infection, or 24 h postinfection. Racivir inhibits HBV replication by 50% at less than 20 nM in human hepatocytes.
CAS:
143491-54-7
Formula:
C8H10FN3O3S
Molecular Weight:
247.24
Purity:
0.98
SMILES:
Nc1nc(=O)n(cc1F)[C@H]1CS[C@@H](CO)O1
References
1. Amancha PK, Hong JJ, Rogers K, Ansari AA, Villinger F. In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. J Immunol. 2013 Dec 15;191(12):6060-70. doi: 10.4049/jimmunol.1302044. PubMed PMID: 24227774; PubMed Central PMCID: PMC3858463.
2. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother. 2011 Jan;12(1):31-46. doi: 10.1517/14656566.2010.509345. Review. PubMed PMID: 20698725.
3. Kohler JJ, Hosseini SH, Cucoranu I, Zhelyabovska O, Green E, Ivey K, Abuin A, Fields E, Hoying A, Russ R, Santoianni R, Raper CM, Yang Q, Lavie A, Lewis W. Transgenic cardiac-targeted overexpression of human thymidylate kinase. Lab Invest. 2010 Mar;90(3):383-90. doi: 10.1038/labinvest.2009.146. PubMed PMID: 20065942; PubMed Central PMCID: PMC2829097.
4. Verhoeven D, Sankaran S, Dandekar S. Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy. J Med Primatol. 2007 Aug;36(4-5):219-27. PubMed PMID: 17669210.